Can I Take Resveratrol with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and Who Uses It?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. By blocking sclerostin, Evenity increases bone formation while simultaneously reducing bone resorption, a dual action no other approved osteoporosis drug achieves. The FDA approved romosozumab in April 2019 for post-menopausal women with severe osteoporosis at high fracture risk.

The approved course is 12 monthly subcutaneous injections (210 mg per month, given as two 105 mg injections). After completing the 12-dose series, prescribers typically transition patients to an antiresorptive agent such as denosumab or a bisphosphonate to preserve the gains.

Who Gets Prescribed Evenity?

Evenity is indicated for post-menopausal women with osteoporosis and a high fracture risk, defined as a prior osteoporotic fracture, a very low T-score (typically below negative 2.5), or multiple clinical risk factors. The FRAME trial, which enrolled 7,180 post-menopausal women, showed romosozumab reduced new vertebral fractures by 73% compared with placebo over 12 months.

A Note on Cardiovascular Risk

Evenity carries a boxed warning. The ARCH trial compared romosozumab to alendronate and found a higher rate of serious cardiovascular events (heart attack, stroke, cardiovascular death) in the romosozumab arm (2.5% vs. 1.9%). Evenity is contraindicated in women who have had a heart attack or stroke within the previous year. This cardiovascular signal matters when you are evaluating any additional supplement, including resveratrol, that carries its own cardiovascular claims.

What Is Resveratrol and Why Do Women Take It?

Resveratrol is a polyphenol stilbene found naturally in red wine, grape skins, blueberries, and Japanese knotweed (Polygonum cuspidatum). Supplement doses range from 150 mg to 1,000 mg per day, far above what any dietary source provides. Women take it for a range of reasons: longevity, cardiovascular protection, anti-inflammatory effects, metabolic support, and, relevant to osteoporosis, potential bone-protective properties.

Resveratrol and Bone: The Evidence So Far

The bone data in women is genuinely limited. A 2015 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism enrolled 66 post-menopausal women and found that 75 mg of resveratrol twice daily for 16 weeks increased lumbar spine bone mineral density by 2.6% compared with placebo. That is a modestly encouraging finding, but the trial was small, short, and has not been replicated at scale.

A 2020 Cochrane-adjacent review of polyphenols and bone health concluded that evidence remains insufficient to recommend resveratrol as a standalone bone-protective agent in women, and noted that most trials lasted less than six months, too short to assess fracture outcomes. NCBI reference on polyphenols and bone.

Resveratrol as a Phytoestrogen: Why This Matters for Women on Evenity

Resveratrol binds estrogen receptors ER-alpha and ER-beta with low affinity, acting as a selective estrogen receptor modulator (SERM)-like compound. Research published in Endocrinology confirmed this binding activity two decades ago, and it remains clinically relevant because estrogen status influences bone turnover. Post-menopausal women on Evenity are in an estrogen-depleted state, and adding a weak estrogenic compound at high supplement doses introduces an unpredictable pharmacodynamic variable, not a dangerous one in most cases, but one worth naming.

Does Resveratrol Interact with Romosozumab? The Mechanism Breakdown

The short answer: no confirmed, clinically documented direct interaction exists. The longer answer requires separating pharmacokinetic from pharmacodynamic concerns.

Pharmacokinetic Interaction: The CYP3A4 Question

Romosozumab is a monoclonal antibody. Monoclonal antibodies are not metabolized by cytochrome P450 enzymes. They are broken down by proteolytic degradation into amino acids, the same pathway as any other large protein. This means the classic CYP3A4 drug-drug interaction concern does not apply to Evenity in the way it would apply to a small-molecule drug.

Resveratrol, on the other hand, is both a substrate and an inhibitor of CYP3A4 and CYP2C9. At high oral doses (500 mg or above), resveratrol may inhibit CYP3A4 sufficiently to raise plasma levels of co-administered CYP3A4-dependent drugs. Because romosozumab bypasses this pathway entirely, no pharmacokinetic interaction is expected or has been reported.

Pharmacodynamic Interaction: Bone Turnover Overlap

This is the more interesting and less well-studied area. Romosozumab works by suppressing sclerostin, which activates Wnt signaling to drive osteoblast activity. Resveratrol has been shown in cell-culture and animal studies to activate the SIRT1 pathway and also to upregulate Wnt/beta-catenin signaling, a potential mechanistic overlap with romosozumab's mechanism. One preclinical study demonstrated that resveratrol stimulated osteoblast differentiation and suppressed osteoclast activity in vitro.

Whether that overlapping mechanism translates to additive benefit, no change, or interference in a living human on Evenity is genuinely unknown. No clinical trial has tested this combination. The honest answer is that we are extrapolating from separate bodies of evidence, not from a head-to-head study.

The WomanRx framework for evaluating this combination separates three risk tiers:

Tier 1 (Low concern): Pharmacokinetic interaction via CYP450. Risk: negligible. Romosozumab is not a CYP substrate.

Tier 2 (Moderate uncertainty): Pharmacodynamic overlap on bone turnover markers. Risk: theoretical and unstudied. May be additive or irrelevant.

Tier 3 (Requires individual assessment): Resveratrol's estrogenic activity in women with hormone-sensitive conditions (e.g., a history of ER-positive breast cancer, or women still in late perimenopause). Risk: low at dietary doses, uncertain at supplement doses above 250 mg/day.

What About Cardiovascular Effects?

High-dose resveratrol (500 mg to 1,000 mg/day) has shown mixed cardiovascular signals in human trials. A 2013 study in Cell Metabolism found that high-dose resveratrol (250 mg/day for 8 weeks) blunted the cardiovascular benefits of exercise training in older adults. Because Evenity already carries a boxed warning for cardiovascular events, adding a supplement with its own cardiovascular complexity warrants a direct conversation with your cardiologist or prescribing clinician, particularly if you have any prior cardiac history.

Sex-Specific Physiology: Why This Question Is Different for Women

Most resveratrol research has been conducted in mixed-sex or male-dominant cohorts. The pharmacokinetics of resveratrol differ by sex: women tend to have higher peak plasma concentrations after equivalent oral doses compared with men, likely due to body composition differences and sex-based differences in gut microbiome composition that affect resveratrol metabolism to active metabolites like dihydroresveratrol. One pharmacokinetic analysis noted sex as a variable in resveratrol bioavailability, though it was not the primary endpoint.

This evidence gap is real. Women have been chronically underrepresented in supplement pharmacokinetic trials, and the data on resveratrol specifically in post-menopausal women on concurrent bone-active therapies is essentially absent. What follows in this article is our best clinical reasoning from adjacent evidence, not from a direct study of this combination.

Life Stage Breakdown

Post-menopausal women (Evenity's approved population). Estrogen deficiency accelerates bone resorption and shifts bone remodeling balance toward net loss. Romosozumab corrects this by forcing formation upward. Resveratrol's weak estrogenic activity at the doses typically in supplements (150 to 500 mg/day) is unlikely to meaningfully alter estrogen receptor signaling in the skeleton, but is also not zero.

Perimenopausal women. Evenity is not approved in this group. If you are perimenopausal with osteopenia or early osteoporosis and using resveratrol as a supplement, the drug-supplement interaction question is not yet relevant to you. Your bone health plan at this stage centers on calcium, vitamin D, resistance training, and addressing hormonal status.

Reproductive-age women and those trying to conceive. Evenity is contraindicated in pregnancy (see section below). Resveratrol has shown anti-proliferative effects in embryo models and is not recommended during conception attempts or pregnancy. Both should be discussed with your provider before any pregnancy planning.

Pregnancy, Lactation, and Contraception: What Every Woman on Evenity Must Know

Romosozumab is contraindicated in pregnancy. Animal studies showed fetal harm at clinically relevant exposures. The FDA label states that romosozumab may cause fetal harm based on findings in animal reproduction studies and the drug's mechanism of action. Because sclerostin plays a role in fetal skeletal development, blocking it during pregnancy carries a theoretical risk of skeletal abnormalities.

Women of reproductive potential receiving Evenity should use effective contraception during treatment and for at least eight months after the last dose, based on the drug's estimated clearance timeline.

Lactation. It is not known whether romosozumab is excreted in human milk. Monoclonal antibodies can transfer into breast milk, though oral bioavailability in a nursing infant is generally low for large-protein biologics. The FDA label advises weighing the benefits of breastfeeding against potential infant risk. Breastfeeding while on Evenity is not automatically prohibited, but it requires an informed discussion with your clinician.

Resveratrol in pregnancy and lactation. No adequate human studies exist on resveratrol safety in pregnancy. Animal data suggests resveratrol at high doses may interfere with fetal development. The ACOG general guidance advises avoiding supplements without clear safety data during pregnancy. Resveratrol falls into that category. During breastfeeding, resveratrol transfer into breast milk is plausible but unstudied, so avoidance is the conservative recommendation.

The bottom line for pregnancy: if you are on Evenity, you should already be using reliable contraception. If a pregnancy occurs during treatment, contact your prescriber immediately and report it to the Amgen pregnancy surveillance program.

Who This Combination Is Right For (and Who Should Pause)

Women Who Can Likely Continue Both with Monitoring

• Post-menopausal women on Evenity with no prior cardiovascular events and no hormone-sensitive cancer history
• Women taking resveratrol at doses below 250 mg/day from food-grade or standardized supplements
• Women whose prescribers are aware of both agents

Women Who Should Have a Direct Clinical Conversation First

• Anyone with a prior heart attack, stroke, or unstable angina (the Evenity boxed warning already applies; adding any vasoactive supplement needs review)
• Women with a personal or first-degree family history of ER-positive breast cancer (resveratrol's estrogenic activity warrants discussion with oncology)
• Women taking anticoagulants such as warfarin or apixaban (resveratrol at high doses may inhibit CYP2C9 and influence INR or drug exposure)
• Women in late perimenopause who have been prescribed Evenity off-label (this is outside the approved indication; discuss comprehensively)

Women Who Should Not Take Resveratrol During Evenity Treatment Without Specialist Input

• Women with a history of hormonally driven conditions (endometriosis, uterine fibroids, hormone-receptor-positive gynecologic cancers) where even weak estrogenic compounds require oncologic or gynecologic review
• Women concurrently on tamoxifen or aromatase inhibitors (resveratrol's estrogenic activity could theoretically interfere with the anti-estrogenic mechanism of these drugs, though direct evidence is sparse)

Practical Guidance: Timing, Dose, and Monitoring

Dose Considerations

If your clinician approves continued resveratrol use during Evenity treatment, lower doses (150 mg to 250 mg/day) minimize the theoretical estrogenic and CYP-related variables. There is no evidence that higher doses (500 mg to 1,000 mg/day) provide meaningfully better bone outcomes, and the cardiovascular signal from the 2013 Cell Metabolism study is reason enough to avoid very high doses in a population already carrying Evenity's cardiovascular boxed warning.

Timing of Administration

Romosozumab is given as a monthly subcutaneous injection by a healthcare provider or trained self-injector. It does not require fasting or dose separation from oral supplements the way some oral drugs do. There is no pharmacokinetic basis for separating resveratrol timing from Evenity injection timing.

What to Monitor

Your prescribing clinician will typically check:

• Bone turnover markers (serum P1NP and CTX) at baseline and during Evenity treatment to confirm the drug is working
• Blood pressure and cardiovascular symptom review at each monthly visit
• Calcium and vitamin D levels, since hypocalcemia is a known Evenity risk and adequate calcium and vitamin D intake is required during treatment (the FDA label recommends at least 1,000 mg calcium and 800 IU vitamin D daily)

If you are taking resveratrol alongside Evenity, mention it explicitly at each visit so your team can note any unexpected changes in bone turnover markers, cardiovascular parameters, or symptom pattern.

Telling Your Prescriber

Many women do not disclose supplement use because they assume supplements are automatically safe or that prescribers will dismiss the question. Your Evenity prescriber needs to know about resveratrol because:

1. The cardiovascular risk context of Evenity means any cardiovascular-active supplement requires documentation
2. If you experience an unexpected outcome, supplement use will be relevant to the clinical picture
3. Bone turnover marker interpretation during treatment may be confounded by concurrent bone-active supplements

The Evidence Gap: What Research Still Needs to Happen

Women deserve direct evidence, not extrapolation. As of early 2025, no published randomized controlled trial has specifically evaluated resveratrol supplementation in women receiving romosozumab. The existing evidence base consists of:

• Animal and in vitro data on resveratrol's bone effects (promising, not conclusive)
• One small human RCT on resveratrol and bone density in post-menopausal women (Ornstrup 2014, n=74, 16 weeks)
• Pharmacokinetic data on resveratrol's CYP450 effects, which do not apply to monoclonal antibody metabolism
• No combined-treatment safety or efficacy study

The FRAME and ARCH trials that established romosozumab's efficacy and safety profile excluded participants on investigational agents but did not systematically report supplement use. This is a standard gap in osteoporosis trial design, not unique to Evenity, but it means we have no randomized data to say whether resveratrol use during the 12-month Evenity course helps, hinders, or does nothing.

The honest clinical position is that the interaction risk is low but unstudied, estrogenic activity at supplement doses is real but probably small in the post-menopausal context, and the cardiovascular overlap deserves individual risk assessment rather than a blanket recommendation either way.

Resveratrol for Bone Health: Should You Rely on It Alongside (or Instead of) Evenity?

Evenity's fracture reduction data is strong. The FRAME trial showed a 73% reduction in new vertebral fractures and a 36% reduction in non-vertebral fractures at 12 months. Resveratrol at 75 mg twice daily showed a 2.6% increase in lumbar bone mineral density in one small trial. These are not equivalent interventions, and resveratrol should not be positioned as an alternative to prescribed osteoporosis therapy.

If you are considering resveratrol because you want to add bone-active support during Evenity treatment, the better-evidenced co-interventions are adequate calcium (1,200 mg/day total from diet and supplement in women over 50, per National Osteoporosis Foundation guidance), vitamin D (800 to 2,000 IU/day depending on baseline 25-OH-D levels), and progressive resistance exercise. These carry more evidence and less uncertainty than resveratrol in this context.